Tokyo Tape
Sign in
← Immuno-Biological Laboratories

Quarterly report · Q3

4570.TEDINET S100Q59N
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥555m2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥648m2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥448m2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥19m2022-04-01 → 2022-12-31Cons.Operating income
Operating income−¥137m2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income−¥68m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥243m2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥233m2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax−¥70m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax−¥237m2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)−¥76m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥259m2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥244m2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income−¥76m2022-04-01 → 2022-12-31Cons.Profit loss
Net income−¥244m2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥1.6bnat 2022-12-31Cons.Assets
Total assets¥1.7bnat 2022-03-31Cons.Assets
Total assets¥1.7bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥338mat 2022-12-31Cons.Liabilities
Total liabilities¥337mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.3bnat 2022-12-31Cons.Net assets
Net assets / equity¥1.4bnat 2022-03-31Cons.Net assets
Net assets / equity¥1.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥394mat 2022-12-31Cons.Cash and deposits
Cash and deposits¥508mat 2022-03-31Cons.Cash and deposits
EPS (basic)¥-8.22022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥6.412022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-27.782021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-26.142021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.742021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio79.3%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio80.7%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 25
SegmentItemPeriodValue
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentrevenue2022-04-01 → 2022-12-31¥3m
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentrevenue external2022-04-01 → 2022-12-31¥3m
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentsegment profit2022-04-01 → 2022-12-31−¥11m
jpcrp040300-q3r_E00986-000Gene Recombination Silkworm Developmentreportable segmentsegment profit2022-04-01 → 2022-12-31−¥61m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentrevenue2022-04-01 → 2022-12-31¥552m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentrevenue external2022-04-01 → 2022-12-31¥552m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentsegment profit2022-04-01 → 2022-12-31¥92m
—segment totalrevenue2022-04-01 → 2022-12-31¥555m
—segment totalrevenue external2022-04-01 → 2022-12-31¥555m
—segment totalsegment profit2022-04-01 → 2022-12-31¥19m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥3m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥3m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31¥560,000
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentrevenue2021-04-01 → 2021-12-31¥12m
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentrevenue external2021-04-01 → 2021-12-31¥12m
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentsegment profit2021-04-01 → 2021-12-31−¥9m
jpcrp040300-q3r_E00986-000Gene Recombination Silkworm Developmentreportable segmentsegment profit2021-04-01 → 2021-12-31−¥78m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentrevenue2021-04-01 → 2021-12-31¥440m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentrevenue external2021-04-01 → 2021-12-31¥436m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥3m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentsegment profit2021-04-01 → 2021-12-31−¥51m
—segment totalrevenue2021-04-01 → 2021-12-31¥451m
—segment totalrevenue external2021-04-01 → 2021-12-31¥448m
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥3m
—segment totalsegment profit2021-04-01 → 2021-12-31−¥137m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 314
ItemContextValueUnit
Gain on sales of noncurrent assets eiPrior1YTDDuration371000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration2537000JPY
Extraordinary incomeCurrentYTDDuration－JPY
Loss on valuation of investment securities elPrior1YTDDuration－JPY
Loss on valuation of investment securities elCurrentYTDDuration1108000JPY
Impairment loss elPrior1YTDDuration7041000JPY
Impairment loss elCurrentYTDDuration804000JPY
Extraordinary lossPrior1YTDDuration7041000JPY
Extraordinary lossCurrentYTDDuration1913000JPY
Income before income taxesPrior1YTDDuration-237404000JPY
Income before income taxesCurrentYTDDuration-69551000JPY
Income taxes currentPrior1YTDDuration6110000JPY
Income taxes currentCurrentYTDDuration6879000JPY
Income taxesPrior1YTDDuration6110000JPY
Income taxesCurrentYTDDuration6879000JPY
Profit lossPrior1YTDDuration-243515000JPY
Profit lossCurrentYTDDuration-76430000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-243515000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-76430000JPY
Profit lossPrior1YTDDuration-243515000JPY
Profit lossCurrentYTDDuration-76430000JPY
Comprehensive incomePrior1YTDDuration-243515000JPY
Comprehensive incomeCurrentYTDDuration-76430000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-243515000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-76430000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration－JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration－JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E00986-000ImmunityRelatedReportableSegmentMember436388000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E00986-000GeneRecombinationSilkwormDevelopmentReportableSegmentMember－JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E00986-000CosmeticsReportableSegmentsMember11693000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember448082000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration448082000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E00986-000ImmunityRelatedReportableSegmentMember3222000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E00986-000GeneRecombinationSilkwormDevelopmentReportableSegmentMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E00986-000CosmeticsReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember3222000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-3222000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E00986-000ImmunityRelatedReportableSegmentMember439610000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E00986-000GeneRecombinationSilkwormDevelopmentReportableSegmentMember－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E00986-000CosmeticsReportableSegmentsMember11693000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember451304000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-3222000JPY
Net salesPrior1YTDDuration448082000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E00986-000ImmunityRelatedReportableSegmentMember-50825000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E00986-000GeneRecombinationSilkwormDevelopmentReportableSegmentMember-77654000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E00986-000CosmeticsReportableSegmentsMember-8758000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember-137238000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass